220 likes | 314 Views
INFLUENZA 2012. Rod Givney Microbiology Infection Prevention & Control Pathology North rodney.givney@hnehealth.nsw.gov.au. Symptoms of influenza. Fever (3 days) Cough Headaches, myalgia, malaise, and anorexia Pharyngeal pain, and nasal obstruction and discharge 1-2 week convalescence
E N D
INFLUENZA 2012 Rod Givney Microbiology Infection Prevention & Control Pathology North rodney.givney@hnehealth.nsw.gov.au
Symptoms of influenza • Fever (3 days) • Cough • Headaches, myalgia, malaise, and anorexia • Pharyngeal pain, and nasal obstruction and discharge • 1-2 week convalescence • mild illness or asymptomatic infection
Complications of influenza • Primary viral pneumonia • Secondary bacterial pneumonia • Streptococcus pneumoniae • Haemophilusinfluenzae • Staphylococcus aureus • Croup, exacerbation COPD; myositis, mycarditis, pericarditis, Guillan-Barré
Diagnosis- PCR • Personal protective equipment (surgical mask, eye goggles) & hand hygeine • sample the anterior nostril by gently abrading the nasal mucosa on both sides • insert swab into transport medium (green top viral ) • Throat, nasopharynx, sputum, lavage
Epidemiology of influenza A • Humans, birds, pigs, horses, marine mammals) • Annual peaks of seasonal influenza, outbreaks • Pandemics B & C • Humans only • B: seasonal, outbreaks • Not pandemic
Virology of influenza A • Genetic “drift”: random nucleotide changes • Genetic “shift” : reassortment • Swapping of genome segments coding for haemagglutinin & neuraminidase proteins • 15 haemagglutinin (HA) types, 9 neuraminidase (NA) types • (B & C: genetic variation only by drift)
Influenza A pandemics • 1918 H1N1 • 20-40 million, 50% in 20-40 years of age • 1957 H2N2 • >10% deaths <65 years • 1968 H3N2 • >50% deaths in 45-65 years • 2009 H1N1 • 150, 000- 0.5 million deaths • Dawood et al. www.thelancet.com/infection Published online June 26, 2012 http://dx.doi.org/10.1016/S1473-3099(12)70121-4
2009 Pandemic • 0-17 years • 44 500 (22 400–80 100) • 18-64 years • 183 700 (98 800–342 200) • >64 years • 56 400 (30 500–233 700)
Avian influenza H5N1 in humans http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/
Treatment • Neuraminidase inhibitors
Prevention (1) • Immunisation • Trivalent vaccine • H3, H1, B • Annual update • Manufacture
Infection control • Droplet or airborne?
http://intranet.hne.health.nsw.gov.au/influenza-like_illness_managementhttp://intranet.hne.health.nsw.gov.au/influenza-like_illness_management
2012 summary • Case= fever + (cough or sore throat) • Droplet precautions with eye protection & surgical mask (&apron) • Staff exclusion • Aerosolising procedures • Patient management • Start & stop, at risk, immunosuppressed • Oseltamivir